LY9 and cancer: Lymphoma patients (Ly1 and Ly2) and cancer-free TET2delA carriers (Ly9, Ly11, and Ly14) were also compared and no skewing toward hypermethylation was observed, although the results should be interpreted with caution due to low number of individuals in this comparison (Supplementary Data 2).